- Home
- VFC vs LEGN Comparison
VFC vs LEGN Comparison
Compare VFC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VFC
- LEGN
- Stock Information
- Founded
- VFC 1899
- LEGN 2014
- Country
- VFC United States
- LEGN United States
- Employees
- VFC N/A
- LEGN N/A
- Industry
- VFC Apparel
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- VFC Consumer Discretionary
- LEGN Health Care
- Exchange
- VFC Nasdaq
- LEGN Nasdaq
- Market Cap
- VFC 7.2B
- LEGN 7.8B
- IPO Year
- VFC N/A
- LEGN 2020
- Fundamental
- Price
- VFC $22.27
- LEGN $34.08
- Analyst Decision
- VFC Hold
- LEGN Strong Buy
- Analyst Count
- VFC 20
- LEGN 13
- Target Price
- VFC $19.26
- LEGN $81.54
- AVG Volume (30 Days)
- VFC 5.4M
- LEGN 1.5M
- Earning Date
- VFC 02-04-2025
- LEGN 11-12-2024
- Dividend Yield
- VFC 1.62%
- LEGN N/A
- EPS Growth
- VFC N/A
- LEGN N/A
- EPS
- VFC N/A
- LEGN N/A
- Revenue
- VFC $10,093,489,000.00
- LEGN $520,183,000.00
- Revenue This Year
- VFC N/A
- LEGN $120.77
- Revenue Next Year
- VFC $2.78
- LEGN $68.54
- P/E Ratio
- VFC N/A
- LEGN N/A
- Revenue Growth
- VFC N/A
- LEGN 122.96
- 52 Week Low
- VFC $11.00
- LEGN $32.50
- 52 Week High
- VFC $23.49
- LEGN $70.13
- Technical
- Relative Strength Index (RSI)
- VFC 61.01
- LEGN 31.74
- Support Level
- VFC $20.70
- LEGN $32.50
- Resistance Level
- VFC $23.49
- LEGN $35.08
- Average True Range (ATR)
- VFC 0.81
- LEGN 1.98
- MACD
- VFC 0.11
- LEGN -0.51
- Stochastic Oscillator
- VFC 62.07
- LEGN 13.10
About VFC V.F. Corporation
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Altra, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.